Introduction
In our study, we tried to analyze genetic changes in a palette of central nervous system (CNS) tumors regarding the roles of three genes, E-cadherin (CDH1), adenomatous polyposis coli (APC) and beta-catenin (CTNNB1). All gene products are components of the adherens junction, where E-cadherin is bound to β-catenin, which in turn binds to the central part of the APC protein (15, 22) . Besides roles in cellular architecture all molecules have roles in wnt signaling, where beta-catenin is the main signaling molecule, and E-cadherin, as currently understood, is indirectly involved in the modulation of the signal (17) . APC protein acts as a negative regulator of the wnt pathway and is a critical component of the beta-catenin destruction machinery heading to the proteasome (6, 19) . In response to wnt signaling, or under the circumstances of mutated APC, beta-catenin is stabilized, accumulates in the cytoplasm and enters the nucleus, where it finds a partner, a member of the DNA binding protein family LEF/TCF (16) . Together they activate new gene expression programs, among others, c-myc and cyclin D1 (9) .
It has been well documented that wnt genes, together with other components of wnt signaling pathway, are implicated in tumorigenesis and lately also in brain tumorigenesis (5, 10) . Our interest in genes of the wnt pathway stemmed principally from several findings.
First, classical cadherins such as E-type and N-type are involved in forming both adherens and synaptic junctions in the nervous system. Moreover, Shimamura and Takeichi (24) found that E-cadherin is transiently expressed in restricted regions of the mouse embryonic and adult brain. New knowledge on wnt signaling shows that wnt proteins regulate critical developmental processes of normal brain development (7, 14) Mutations of beta-catenin gene have been reported in sporadic medulloblastoma (28) and in 2003. beta-catenin was identified as a critical factor for dendritic morphogenesis (29) .
APC has been thought of primarily as a colon-specific tumor suppressor gene, but its critical involvement in particular syndromes, like the Tourcot syndrome, which includes the development of primary brain tumors (8) , and APC's high expression in the CNS suggests that it performs important functions in these tissues also (1) .
Genetic background of specific histopathological type of brain tumor still needs to be elucidated. In this paper we offer three new candidates to fill in the puzzle of genetic basis of human brain tumors.
Materials and methods

Tumor specimen
Samples of 50 central nervous system tumors together with 50 autologous blood tissues were collected from the Department of Neurosurgery, University Hospital "Sisters of Charity", Zagreb, Croatia. Using the magnetic resonance imaging (MRI) tumor lesions were found in different cerebral regions (predominantly temporal and parietal region), with the surrounding zone of perifocal oedema (table 1) . During the operative procedure the tumor was removed using a microneurosurgical technique. The patients had no family history of brain tumors and did not undergo chemotherapy or radiotherapy prior to surgery. Collected tumor tissues were frozen in liquid nitrogen and transported to the laboratory, where they were immediately transferred at -75°C. The peripheral blood samples were collected in EDTA and processed immediately. All tumors were studied by pathologists and classified according to the WHO criteria. There were 36% of glioblastomas (18/50); 30% meningiomas (16/50); 12% astrocytomas (6/50); 12% neurinomas (Schwannomas) (6/50); one germinoma (2%), one oligoastrocytoma, one ganglioma and one medulloblastoma. The glioblastomas we considered primary because the diagnosis of glioblastoma was made at the first biopsy, without clinical or histopathologic evidence of a less malignant precursor lesion.
Thirty patients were female (60%), and twenty male (40%). The age of patients varied from 13 to 77 (mean age=51.8). The mean ages at diagnosis for both sexes were similar (M = 52.6; F = 51.3).
The local Ethical Committee approved our study and patients gave their informed consent.
DNA extraction.
Tumor sample for DNA isolation was the part of obvious tumor mass evaluated by the neurosurgeon and based on macroscopic appearance and tissue color, density, and consistency on gross section. The sample was also evaluated for the percentage of tumor cells by pathologist and consisted of more than 85% of tumor cells. Genomic DNA was isolated from unfixed frozen tumor samples and peripheral blood leucocytes by standard methods using proteinase K and phenol chloroform.
Polymerase chain reaction
The D16 S752 (GATA51G03) polymorphic region linked to the E-cadherin gene was The optimal reaction mixture (25 µl) for APC's exon 11 and 15 amplification as well as PCR conditions were described previously (18) .
The reaction mixture (25 µl) for CTNNB1's exon 3 amplification was: 10 pmol of each primer (5´-CCA ATC TAC TAA TGC TAA TAC TG-3´ and 5´-CTG CAT TCT GAC TTT CAG TAA GG -3´), 200-400 ng template DNA, 2.5 µl PCR buffer, 2.5 mM MgCl 2 , 2.5 mM of each dNTP, 0.5 U Taq polymerase (Eppendorf, Germany). PCR conditions were the same as already described for CDH1 gene.
All PCR products were analyzed on 2% agarose gels.
Loss of heterozygosity
To discover LOH of the E-cadherin gene, a polymorphic marker D16S752, was chosen from the Genome DataBase. Heterozygous samples were visualized on 15%
polyacrylamide gels, stained with silver and on Spreadex EL 300 gels (Elchrom scientific, Switzerland), stained with SyberGold (Molecular Probes, Netherlands). Absence or significant decrease in the intensity of one of D16S752 alleles in tumor compared to the autologous blood sample was considered as LOH of CDH1 gene.
LOH of the APC gene was detected on the basis of restriction fragment length polymorphism (RFLP) of the PCR products. Two different polymorphisms were investigated.
One is an Rsa I polymorphic site in exon 11, and the other is an Msp I polymorphic site in exon 15. PCR amplification of exon 11 generated a 133-bp fragment that is cleaved to 85- 
Statistical Analysis
All statistical evaluations were performed according to the SPSS statistical package (SPSS Inc., Chicago, IL, USA).
Results
The pathohistological diagnosis of the analyzed sample, tumor localization and the duration of symptoms are shown in table 1.
The polymorphic marker for E-cadherin gene, D16S752, was highly informative 42/50 (84%), which means that high percent of patients were heterozygous for this polymorphism.
D16S752 is a polymorphic GATA tetranucleotide repeat that could show 7 different allelic variants in Croatian population.
The results of our analysis showed 6 samples with LOH of the CDH1 gene out of 42 heterozygous patients (14.3%) when tumor DNA was compared to autologous constitutive DNA. LOHs of the CDH1 gene were confined to meningiomas. Thirty one % (5/16) of total meningioma sample examined showed LOH of the CDH1 gene, which is shown in Figure 1 .
The correlation between meningiomas and changes of the CDH1 was according to Spearman's test significant at the 0.002 level.
One LOH was also found in a single case of germinoma, while other tumor types did not demonstrate changes of the CDH1 gene. Since they are more frequent in glioblastomas, and scarcer in astrocytomas, it seems that those changes do not represent an initiation event but rather come along the path of astrocytic progression.
A considerable number of changes (27%) of the APC gene was also found in meningiomas, showing that yet another wnt component is involved in their genesis. Wrobel and co-workers (27) reported on increased expression of beta-catenin and cyclin D1 in meningiomas they examined by microarray, but unfortunately did not study APC expression profile.
One LOH of APC gene was found in six informative neurinomas (17%). This is to our knowledge the first report on changes of this gene in neurinoma, but it is difficult to assess the biologic impact of this change.
The observed genetic changes of the APC gene are dispersed among different tumor types, indicating once again that APC is not the first event in the formation of specific brain tumor.
The results of heteroduplex analysis of beta-catenin's exon 3 showed 10% of tumor samples with additional bands suggesting that those brain tumors harbour mutations of the CTNN1 gene. We targeted exon 3 of CTNNB1 gene since it has been reported as mutational hot spot. As for beta-catenins changes, they were not very frequent nor were they exclusive to specific tumor type probably due to a small number of tumors in some of the subsets we investigated. Although beta-catenin is frequently mutated in medulloblastoma and was recently proposed a prognostic factor for medulloblastoma (4), our medulloblastoma sample did not demonstrate mutations of beta-catenin, but showed allelic imbalance at both APC's exons. This finding is not unusual since many investigations (11, 13, 28) collectively demonstrated that approximately 15% of medulloblastomas harbor mutations in APC, betacatenin or Axin. These mutations are mutually exclusive which is supported with our result.
The results reported in this paper indicated that changes of E-cadherin are involved in meningiomas, while changes of APC gene are more commonly distributed among different tumor types, with glioblastomas showing the highest percentage of changes. The functional consequences of the changes we found at the genetic level, would need to be confirmed in future studies at the protein level.
Our findings may contribute to better understanding of brain tumors genetic profile and could be used as prognostic marker of disease evolution and progression. 
